Table 1.
Self-reported baseline clinical characteristics of study participants (n = 2118)
| Women, n (%) | 1569 (74) |
| Age (years), mean (SD) | 70 (4) |
| Age (years), median (IQR) | 70 (65–89) |
| Smoking, n (%) | 140 (7) |
| CHA2DS2-VASc risk score, mean (SD) | 2.6 (0.8) |
| CHA2DS2-VASc risk score, median (IQR) | 2 (2–3) |
| Heart failure, n (%) | 36 (2) |
| Hypertension, n (%) | 910 (43) |
| Diabetes mellitus, n (%) | 156 (7) |
| Previous stroke/TIA, n (%) | 64 (3) |
| Peripheral artery disease, n (%) | 19 (1) |
| Myocardial infarction, n (%) | 119 (6) |
| Chronic obstructive pulmonary disease, n (%) | 96 (5) |
| Anticoagulation therapy, n (%) | 25 (1) |
| Antiplatelet therapy, n (%) | 493 (23) |
| Antihypertensive therapya, n (%) | 523 (25) |
| Beta blocker, n (%) | 273 (13) |
aAngiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.
IQR, interquartile range; TIA, transient ischaemic attack; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74 and sex category (female); SD, standard deviation.